CBP/p300 acetyltransferase activity in hematologic malignancies
- PMID: 27380996
- DOI: 10.1016/j.ymgme.2016.06.013
CBP/p300 acetyltransferase activity in hematologic malignancies
Abstract
CREB binding protein (CBP) and p300 are critical regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities. Loss or mutation of CBP/p300 results in hematologic deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment. Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematologic cancers. Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases.
Keywords: CBP; CREB-binding protein; Hematologic malignancies; Lysine acetyltransferase activity; Targeted therapy; p300.
Copyright © 2016 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
